Although many immune-directed treatments have largely been unsuccessful in glioma, recent work has demonstrated that the IDH mutation leads to immunosuppression in the tumor microenvironment [64,65,66] and that IDH inhibitors can reverse this immunosuppressive environment [67]. Here, IDH1 is linked to neoplasm.